Effects of a new inhaler on lung function and breathlessness in COPD patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, prospective, non-randomized, single-arm study aims to investigate the effects of the inhaled therapy TRIXEO AEROSPHERE on ventilation patterns and lung function in patients with chronic obstructive pulmonary disease (COPD). Participants will be adults aged 40-75 with a documented history of COPD and significant dyspnea. The study will assess the mechanism of action of the treatment and its impact on breathlessness and lung function variability. The study will not involve randomization, allowing for a focused examination of the treatment's effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Provision of signed informed consent prior to any study specific procedure
* Female or male subjects aged 40-75 years inclusive at the time of enrolment (Visit 1)
* Documented history of COPD with a post-bronchodilator FEV1/FVC \<0.70 and a post-bronchodilator 30 % \< FEV1 \<70% of predicted normal value (according to ERS 1993 reference values for spirometry ) at screening
* Smoking history \> 10 pack-years
* Baseline significant dyspnea with a mMRC ≥ 2

Exclusion Criteria:

* History or current diagnosis of asthma or ACOS (asthma-COPD overlap syndrome)
* Respiratory infection or COPD exacerbation within 6 weeks (2 months if it resulted in hospitalization) prior to screening
* Clinically significant or relevant cardiovascular conditions, laboratory tests, electrocardiogram (ECG) parameters:

  * Unstable angina/acute coronary syndrome, or Coronary Artery Bypass Grafting (CABG), Percutaneous Coronary Intervention (PCI) or myocardial infarction within the past 6 months.
  * Congestive heart failure New York Heart Association (NYHA) class III/IV.
  * Structural heart disease (hypertrophic cardiomyopathy, significant valvular disease).
  * Paroxysmal (within the past 6 months) or symptomatic chronic cardiac tachyarrhythmia.
  * Left bundle branch or high-degree AV block (second degree AV block type 2 and third degree AV block) unless the patient has a pacemaker.
  * Sinus node dysfunction with pauses.
  * Ventricular pre-excitation and/or Wolff-Parkinson-White syndrome.
  * QTcF interval \>470 msec (QT interval corrected using Fridericia's formula; QTcF=QT/\[RR1/3\]).
  * Any other ECG abnormality deemed clinically significant by the Investigator.
  * Bradycardia with ventricular rate \< 45 bpm.
  * Uncontrolled hypertension (\> 165/95 mmHg).
* Clinically relevant respiratory conditions (other than COPD)
* Severe renal impairment eGFR \< 30
* Hepatic impairment
* Narrow-angle glaucoma that, in the opinion of the Investigator, has not been adequately treated.
* Symptomatic prostatic hypertrophy or bladder neck obstruction/urinary retention that is clinically significant
* Patients not able to perform IOS, spirometry, plethysmography, or VT acquisition (10 min)
* Any contraindication to LABA or LAMA drugs or to Inhaled corticosteroids
* Pregnancy or breastfeeding
* Woman of childbearing age without effective contraception
* Any type of cancer within 5 years
* Patients under guardianship
* Refuse or incapacity to give an informed consent
* Absence of social insurance

Where it's running

• CHU de Lille
  Lille, France Recruiting

Study contacts

• Principal investigator: Thierry PEREZ, MD — University Hospital, Lille
• Study coordinator: Thierry PEREZ, MD
• Email: thierry.perez@chu-lille.fr
• Phone: 0320445962

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AERO-007: a inhaled LABA+LAMA combination for COPD through a nebulizer

  This study tests whether a nebulized LABA+LAMA combination can improve lung function in adults with COPD.

  Recruiting Phase 2 AeroRx Therapeutics Inc. · London and 1 other locations · NCT07896252

• Cognitive load and inhaler technique in COPD

  This study tests whether adding a short memory task while using an inhaler makes COPD patients more likely to misuse their inhaler.

  Recruiting Spitalul Clinic de Boli Infecțioase și Pneumoftiziologie Dr. Victor Babeș Timișoara · Timișoara, Timiș County · NCT07786220

• Balance training after pulmonary rehab for COPD to help steadiness and reduce falls

  A COPD-focused balance training program called Sport4Steadiness is being tested to see if people with COPD will accept it and if the study processes work well.

  Recruiting at 3 sites Teesside University · Middlesbrough and 2 other locations · NCT07750821

• Continuous vs High-Intensity Interval Exercise in COPD

  This study tests whether continuous versus high-intensity interval exercise affects cerebral oxygenation in people with COPD.

  Recruiting George Papanicolaou Hospital · Thessaloniki, Exohi · NCT07707271

• Biomarker clues for COPD, IPF, and lung cancer

  This study tests whether inflammation, immune, genetic, and epigenetic markers at enrollment can explain how COPD, IPF, or lung cancer present and behave, in order to see if these markers can predict outcomes over a year.

  Recruiting Fondazione Don Carlo Gnocchi ETS · Milan, Milan · NCT07707245

• HRS-9821 Inhalation Suspension for COPD: Safety and Dose Finding in Adults

  This study tests whether HRS-9821 inhalation can be safely taken and help people with moderate to severe COPD, and aims to find a reasonable dose.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Shanghai, Shanghai Municipality · NCT07640451

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.